Aileron Therapeutics, Inc. — Form 10-Q Summary
Filing identity: The provided filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc. It covers the three months ended March 31, 2018 and was filed May 9, 2018. The financial statements are unaudited.
Business Context and Reporting Period
Aileron is a clinical-stage biopharmaceutical company developing stapled-peptide therapeutics. Its lead candidate, ALRN-6924, targets MDMX and MDM2 to reactivate p53-mediated tumor suppression. Multiple clinical trials were ongoing, including Phase 1 studies in advanced solid tumors, lymphoma, AML and MDS, a Phase 2a PTCL trial, and a Phase 1b AML/MDS combination trial.
The company had no approved products or product revenue and expected to generate operating losses for the foreseeable future.
Key Financial Metrics
| Metric | Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $4.846 million | $2.942 million | +$1.904 million |
| General and administrative expense | $2.917 million | $1.647 million | +$1.270 million |
| Total operating expenses | $7.763 million | $4.589 million | +$3.174 million |
| Loss from operations | $(7.763) million | $(4.589) million | $(3.174) million |
| Interest income | $0.175 million | $0.032 million | +$0.143 million |
| Net loss | $(7.588) million | $(4.557) million | $(3.031) million |
| Net loss per share | $(0.52) | $(10.58) | Improved denominator after IPO |
| Net cash used in operating activities | $(6.929) million | $(5.952) million | $(0.977) million |
Revenue and gross margin were not meaningful because the company had no product sales. The operating loss margin cannot be meaningfully calculated against zero revenue. Stock-based compensation expense was $0.767 million, compared with $0.197 million in the prior-year quarter.
At March 31, 2018, cash and cash equivalents were $6.782 million, investments were $36.509 million, and total cash, cash equivalents and investments were $43.291 million. Total assets were $45.831 million, total liabilities were $4.856 million, and stockholders’ equity was $40.975 million. The filing reported no debt.
Cash, cash equivalents and restricted cash declined by $4.513 million during the quarter to $7.438 million. Investing activities provided $2.400 million, primarily from $9.955 million of investment maturities or sales, partly offset by $7.548 million of investment purchases. Financing activities provided $0.016 million from stock-option exercises.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 65%, primarily from higher ALRN-6924 and p53-program spending and increased unallocated personnel and research costs.
- ALRN-6924 and p53-program spending increased to $2.591 million from $1.736 million, reflecting expanded nonclinical combination research.
- General and administrative expense increased 77%, driven by higher personnel, stock compensation and public-company professional fees.
- Net loss increased to $7.588 million from $4.557 million, while operating cash burn increased to $6.929 million from $5.952 million.
- Interest income increased because of the larger investment portfolio following the July 2017 initial public offering.
- Weighted-average shares increased substantially following the IPO and conversion of preferred stock, reducing reported loss per share despite the higher total net loss.
- The company granted options to purchase 110,000 shares at a weighted-average exercise price of $9.02 and had 2.176 million options outstanding at March 31, 2018.
Outlook, Liquidity, Risks and Unusual Items
Management stated that the $43.291 million of cash, cash equivalents and investments at March 31, 2018 was expected to fund operating expenses and capital expenditures into the second half of 2019. The financial statement liquidity disclosure stated that these resources were expected to fund operations for at least the next twelve months. Management emphasized that these estimates depend on assumptions that may prove incorrect and that additional capital will be required.
- The company expected research and development and general and administrative expenses to continue increasing as clinical programs, personnel, facilities and public-company activities expand.
- A new eight-year lease for approximately 18,609 square feet of office and laboratory space in Watertown, Massachusetts became effective April 4, 2018. The initial-term minimum rent commitment was approximately $8.771 million, plus operating expenses, and a $0.568 million security deposit was provided through a letter of credit.
- The existing Cambridge lease was extended through August 31, 2018, with $0.236 million of minimum payments during the extension period.
- The company had no material legal proceedings and no off-balance-sheet arrangements.
- Key risks included dependence on ALRN-6924, uncertain clinical and regulatory outcomes, potential need for a companion diagnostic for wild-type p53 patients, reliance on contract manufacturers and clinical research organizations, intellectual-property and license-compliance risks, competition, patient-enrollment delays and the need for additional financing.
- Harvard had previously asserted a potential diligence breach under the company’s license agreement, but had not further asserted the claim or sought termination as of the filing date. Loss of key license rights could materially affect ALRN-6924 development.
- The company held orphan-drug designation for ALRN-6924 in AML, but designation did not assure approval or commercial success.
- Management reported effective disclosure controls and procedures as of March 31, 2018, with no material change in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Aileron Therapeutics, Inc., despite the request identifying Rein Therapeutics, Inc.
- Review subsequent clinical-trial results, regulatory interactions, enrollment progress and any safety findings for ALRN-6924.
- Assess the company’s cash runway against actual quarterly operating cash burn and the timing and terms of future financing.
- Evaluate the financial impact of the new Watertown facility lease and related build-out costs.
- Review the status of the Harvard/DFCI license dispute and the scope, validity and remaining term of material intellectual-property rights.
- Monitor dilution from future equity or convertible-debt financings and outstanding stock options.